Hypertrophic cardiomyopathy

This trial tests an experimental drug called HRS-1893 in people with non-obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and makes it harder for the heart to pump blood. The study will see if the drug is safe and whether it can improve exercis…

This study tests a new, less invasive procedure called PIMSRA for children with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is too thick and blocks blood flow. The procedure uses a needle guided by ultrasound to deliver radiofrequency energy to the…

This study looked at 100 people with hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Researchers compared different surgical techniques—removing part of the thickened heart muscle alone or combined with repairing the mitral valve—to…

This study tested a new drug called aficamten against the standard medicine metoprolol in 175 adults with a heart condition that makes the heart muscle thick and blocks blood flow. The goal was to see which drug better improves exercise ability and symptoms like shortness of brea…

This study looked at 222 adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Researchers compared those who took mavacamten (Camzyos) with those on standard therapy, measuring changes in heart function and sympto…

This Phase 3 trial tested a daily pill called aficamten in 282 adults with a type of thickened heart muscle that blocks blood flow and causes symptoms like shortness of breath and chest pain. Participants received either aficamten or a placebo for 24 weeks. The main goal was to s…

This study tested a new daily pill called CK-3773274 (aficamten) in 96 adults with symptomatic hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The goal was to find the right dose and check safety, including effects on heart pumping strength. P…

This study looked at the long-term safety of the drug mavacamten in adults with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. About 314 people who had already finished earlier studies took part. The goal was to track side effects over time, not to cure…

This study tested a drug called mavacamten in 38 Japanese adults with a condition where the heart muscle is too thick, making it hard for the heart to pump blood. The goal was to see if the drug could improve heart function and symptoms over 30 weeks. Participants took the drug a…

This study tested a drug called aficamten in 40 Chinese patients with a type of heart disease where the heart muscle is too thick and blocks blood flow. The goal was to see if the drug is safe and helps the heart work better over time. Patients who had already been in a similar s…

This study looked at 115 Canadian adults with obstructive hypertrophic cardiomyopathy (oHCM) who started taking mavacamten as part of routine care. Researchers reviewed patient charts to see if the drug improved heart function and symptoms. The goal was to understand how mavacamt…

This study tested whether the drug trientine can reduce heart muscle thickening and improve exercise ability in people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick. 154 adults with HCM took either trientine or a placebo for 1…

This study looked at 163 patients with obstructive hypertrophic cardiomyopathy who were prescribed mavacamten at a single US hospital. Researchers collected information on symptoms, heart function, and patient characteristics from medical records. The goal was to see how the drug…

This study tested a new MRI technique using a contrast agent called mangafodipir to measure how well heart cells take up manganese, which reflects cell function. It included 44 participants: healthy volunteers and people with heart failure with preserved ejection fraction caused …

This phase 2 trial tested a drug called BX1514M in 38 people with hypertrophic cardiomyopathy, a genetic heart condition that can cause shortness of breath, chest pain, and dizziness. The drug aims to improve blood flow by tightening veins, which may reduce blockages in the heart…

This study looks at whether natural substances in the blood, called cardiac biomarkers, can help doctors manage children with cardiomyopathy—a disease of the heart muscle. The goal is to see if these blood tests could be a less invasive alternative to echocardiograms or MRIs for …

This study looks at how inherited heart rhythm problems (like Long QT Syndrome) and heart muscle diseases (like Hypertrophic Cardiomyopathy) affect the quality of life and physical activity of children aged 6 to 18. Researchers will compare 107 children with these conditions to 1…

This study reviewed information from 683 adults with obstructive hypertrophic cardiomyopathy who took mavacamten through a support program in Canada. Researchers looked at patient characteristics and how long they stayed on the medication. The goal was to understand real-world us…

This study looked at how blood vessel function relates to heart blockage in people with a genetic heart condition called hypertrophic cardiomyopathy. Researchers measured blood flow and vessel flexibility in 40 adults. The goal was to understand the connection, not to test a trea…

This study collected information from over 15,000 people hospitalized with cardiomyopathy, a heart muscle disease. Researchers looked at how much these hospital stays cost and what the money was spent on. The goal was to understand the real-world financial impact and help manage …

This pilot study enrolled 5 people with hypertrophic cardiomyopathy who needed an implantable cardioverter defibrillator (ICD) but did not require pacing. Participants were randomly assigned to receive either a subcutaneous ICD (placed under the skin) or a transvenous ICD (with l…

This early-phase trial tested a single oral dose of HRS-1893 in 20 healthy white male volunteers to see how the body processes the drug and whether it is safe. The study is a first step toward potentially treating hypertrophic cardiomyopathy, a condition where the heart muscle th…

This study looked for Fabry disease, a rare genetic disorder, in 409 Portuguese adults with unexplained heart muscle diseases. Researchers tested patients with different types of cardiomyopathy to see how many actually had Fabry disease. The goal was to better understand how comm…

This completed study looked at 258 people with different types of cardiomyopathy (a disease of the heart muscle) to see if special imaging could predict stroke risk. Researchers used echocardiograms and MRI scans to measure blood flow in the heart and check for silent brain infar…

This completed Phase 1 study looked at how HRS-1893 tablets are processed in people with mild or moderate kidney impairment compared to healthy subjects. The goal was to understand dosing needs for patients with hypertrophic cardiomyopathy who also have kidney issues. Twenty-four…